Valeo Financial Advisors’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-13,003
| Closed | -$513K | – | 777 |
|
|
2025
Q1 | $513K | Sell |
13,003
-529
| -4% | -$20.9K | 0.01% | 408 |
|
|
2024
Q4 | $407K | Buy |
13,532
+3,309
| +32% | +$99.6K | 0.01% | 450 |
|
|
2024
Q3 | $239K | Buy |
+10,223
| New | +$239K | 0.01% | 595 |
|
|
2024
Q2 | – | Sell |
-43,344
| Closed | -$606K | – | 685 |
|
|
2024
Q1 | $606K | Sell |
43,344
-19,956
| -32% | -$279K | 0.02% | 320 |
|
|
2023
Q4 | $1.08M | Buy |
63,300
+1,500
| +2% | +$25.6K | 0.04% | 213 |
|
|
2023
Q3 | $517K | Buy |
61,800
+1,500
| +2% | +$12.5K | 0.02% | 323 |
|
|
2023
Q2 | $1.5M | Sell |
60,300
-5,000
| -8% | -$124K | 0.07% | 153 |
|
|
2023
Q1 | $982K | Sell |
65,300
-3,500
| -5% | -$52.6K | 0.05% | 216 |
|
|
2022
Q4 | $814K | Buy |
68,800
+35,900
| +109% | +$425K | 0.04% | 212 |
|
|
2022
Q3 | $195K | Sell |
32,900
-9,100
| -22% | -$53.9K | 0.01% | 438 |
|
|
2022
Q2 | $178K | Buy |
42,000
+24,900
| +146% | +$106K | 0.01% | 436 |
|
|
2022
Q1 | $163K | Sell |
17,100
-5,500
| -24% | -$52.4K | 0.01% | 531 |
|
|
2021
Q4 | $429K | Buy |
22,600
+6,400
| +40% | +$121K | 0.02% | 332 |
|
|
2021
Q3 | $539K | Buy |
+16,200
| New | +$539K | 0.03% | 268 |
|
|
2021
Q2 | – | Sell |
-1,000
| Closed | -$48K | – | 1598 |
|
|
2021
Q1 | $48K | Buy |
1,000
+500
| +100% | +$24K | ﹤0.01% | 854 |
|
|
2020
Q4 | $26K | Hold |
500
| – | – | ﹤0.01% | 945 |
|
|
2020
Q3 | $13K | Buy |
+500
| New | +$13K | ﹤0.01% | 987 |
|